Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

824
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
824
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

772
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
772
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

656
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
656
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

598
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
598
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

841
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
841
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

732
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
732

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of Patients With Reduced Left Ventricular Function Undergoing Left Atrial Appendage Occlusion.

JACC. Clinical electrophysiology·2026
Same author

Rechallenge of 5-Fluorouracil in a Patient With Coronary Vasospasm Unable to Receive Oral Medications.

JACC. Case reports·2025
Same author

Long-Term Outcomes Following Left Atrial Appendage Occlusion in Medicare Beneficiaries: Outcomes From the National Cardiovascular Data Registry.

Journal of the American Heart Association·2025
Same author

Comparing Claims Data to Stroke and Bleeding in the NCDR Left Atrial Appendage Occlusion Registry.

JACC. Advances·2025
Same author

Association of Physician Certification and Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion.

JACC. Cardiovascular interventions·2024
Same author

Construction and characterization of DNA libraries from cultured phages and environmental viromes.

Applied and environmental microbiology·2024

Related Experiment Video

Updated: Apr 4, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K

Chemotherapy-induced cardiomyopathy.

Angela Y Higgins1, Thomas D O'Halloran2, James D Chang2

  • 1Department of Medicine, Beth Israel Deaconess Medical Center, Deaconess Building, Suite 306, One Deaconess Road, Boston, MA, 02215, USA. angela.y.higgins@gmail.com.

Heart Failure Reviews
|September 5, 2015
PubMed
Summary

Cancer treatments can cause heart damage (cardiomyopathy) in survivors. Early recognition and management are crucial for improving long-term outcomes in patients receiving antineoplastic drugs.

Keywords:
CancerCardio-oncologyCardiomyopathyChemotherapyHeart failure

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.5K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.8K

Related Experiment Videos

Last Updated: Apr 4, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.5K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.8K

Area of Science:

  • Cardio-oncology
  • Oncology
  • Cardiology

Background:

  • Antineoplastic drug therapy can lead to cardiomyopathy, a significant concern for cancer survivors.
  • Improved cancer treatment efficacy has increased the relevance of cardiotoxicity, potentially worsening prognosis.
  • Cardio-oncology has emerged to address the mechanisms, prevention, and treatment of these cardiac conditions.

Purpose of the Study:

  • To review chemotherapeutic agents linked to cardiomyopathies.
  • To discuss diagnostic methods for chemotherapy-induced cardiomyopathy.
  • To outline prevention and treatment strategies for cardiotoxicity.

Main Methods:

  • Review of literature on antineoplastic agents and cardiotoxicity.
  • Focus on agents causing cardiomyopathy, including anthracyclines and tyrosine kinase inhibitors.
  • Examination of diagnostic modalities, prevention, and treatment strategies.

Main Results:

  • Chemotherapy, from anthracyclines to targeted agents, can induce various cardiotoxic effects, including cardiomyopathy.
  • Diagnostic tools are available to identify chemotherapy-induced heart conditions.
  • Prevention and treatment strategies can improve survival for cancer patients with cardiotoxicity.

Conclusions:

  • Cardiomyopathy is a critical adverse outcome of antineoplastic therapy.
  • Understanding and managing cardiotoxicity is essential for oncologists and cardiologists.
  • Effective strategies for diagnosis, prevention, and treatment can enhance the quality of life and survival for cancer survivors.